PT2921172T - Combinação dum inibidor de redutase hmg-coa e dum inibidor de sintase de farnesil-pirofosfatase para tratar doenças relacionadas com a acumulação e/ou a persistência de proteinas preniladas - Google Patents

Combinação dum inibidor de redutase hmg-coa e dum inibidor de sintase de farnesil-pirofosfatase para tratar doenças relacionadas com a acumulação e/ou a persistência de proteinas preniladas

Info

Publication number
PT2921172T
PT2921172T PT15160222T PT15160222T PT2921172T PT 2921172 T PT2921172 T PT 2921172T PT 15160222 T PT15160222 T PT 15160222T PT 15160222 T PT15160222 T PT 15160222T PT 2921172 T PT2921172 T PT 2921172T
Authority
PT
Portugal
Prior art keywords
pyrophosphatase
farnesyl
hmg
persistence
accumulation
Prior art date
Application number
PT15160222T
Other languages
English (en)
Inventor
Levy Nicolas
Cau Pierre
Lopez-Otin Carlos
Original Assignee
Univ Aix Marseille
Ass Francaise Contre Les Myopathies Afm
Assist Publique Hopitaux De Marseille
Univ Oviedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aix Marseille, Ass Francaise Contre Les Myopathies Afm, Assist Publique Hopitaux De Marseille, Univ Oviedo filed Critical Univ Aix Marseille
Publication of PT2921172T publication Critical patent/PT2921172T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT15160222T 2006-07-05 2007-07-05 Combinação dum inibidor de redutase hmg-coa e dum inibidor de sintase de farnesil-pirofosfatase para tratar doenças relacionadas com a acumulação e/ou a persistência de proteinas preniladas PT2921172T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0606097A FR2903312B1 (fr) 2006-07-05 2006-07-05 Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament

Publications (1)

Publication Number Publication Date
PT2921172T true PT2921172T (pt) 2018-11-09

Family

ID=37729451

Family Applications (2)

Application Number Title Priority Date Filing Date
PT78038494T PT2034985E (pt) 2006-07-05 2007-07-05 Combinação dum inibidor de redutase hmg-coa e dum inibidor de sintase de farnesil-pirofosfatase para tratar doenças relacionadas com a acumulação e/ou a persistência de proteínas preniladas
PT15160222T PT2921172T (pt) 2006-07-05 2007-07-05 Combinação dum inibidor de redutase hmg-coa e dum inibidor de sintase de farnesil-pirofosfatase para tratar doenças relacionadas com a acumulação e/ou a persistência de proteinas preniladas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT78038494T PT2034985E (pt) 2006-07-05 2007-07-05 Combinação dum inibidor de redutase hmg-coa e dum inibidor de sintase de farnesil-pirofosfatase para tratar doenças relacionadas com a acumulação e/ou a persistência de proteínas preniladas

Country Status (11)

Country Link
US (3) US8518914B2 (pt)
EP (2) EP2921172B1 (pt)
JP (2) JP5363979B2 (pt)
DK (2) DK2921172T3 (pt)
ES (2) ES2702062T3 (pt)
FR (1) FR2903312B1 (pt)
HK (1) HK1214965A1 (pt)
PL (2) PL2921172T3 (pt)
PT (2) PT2034985E (pt)
TR (1) TR201815511T4 (pt)
WO (1) WO2008003864A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903312B1 (fr) * 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
AU2013251237B2 (en) * 2008-01-03 2016-03-17 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
FR2926020B1 (fr) * 2008-01-03 2010-08-13 Univ Aix Marseille Ii Composition cosmetique et/ou dermatologique
EP2261214A1 (en) 2009-06-12 2010-12-15 Splicos Sas Compounds useful to treat premature aging and in particular progeria
KR101982461B1 (ko) 2009-06-12 2019-05-24 아비박스 조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
EP2626069A4 (en) * 2010-10-06 2014-03-19 Univ Tokyo A MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF A DERY LYMPH
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
WO2014210538A1 (en) * 2013-06-28 2014-12-31 The Regents Of The University Of California Treating cognitive deficits associated with noonan syndrome
HRP20211839T1 (hr) 2013-07-05 2022-03-04 Abivax Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3473253A1 (en) 2014-10-29 2019-04-24 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526936A3 (en) * 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US20030105121A1 (en) 1999-07-27 2003-06-05 Bernard Bihari Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
AU2001268653A1 (en) 2000-06-28 2002-01-08 Supergen, Inc. Combination hiv therapy including camptothecin
FR2825706B1 (fr) * 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
GB0220885D0 (en) 2002-09-09 2002-10-16 Novartis Ag Organic compounds
ES2209658B1 (es) 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
CA2509731A1 (en) 2002-12-16 2004-07-22 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
AU2005210093A1 (en) 2004-01-29 2005-08-18 Laboratoires Serono Sa Methods and compositions for the treatment of lipodystrophy
FR2866724B1 (fr) * 2004-02-20 2007-02-16 Atmel Nantes Sa Dispositif de generation d'une tension electrique de reference de precision amelioree et circuit integre electronique correspondant
FR2903312B1 (fr) * 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
FR2926020B1 (fr) 2008-01-03 2010-08-13 Univ Aix Marseille Ii Composition cosmetique et/ou dermatologique

Also Published As

Publication number Publication date
US20130281408A1 (en) 2013-10-24
EP2034985A1 (fr) 2009-03-18
EP2921172A1 (fr) 2015-09-23
PL2921172T3 (pl) 2019-06-28
EP2034985B1 (fr) 2015-05-06
TR201815511T4 (tr) 2018-11-21
JP2009541475A (ja) 2009-11-26
US9072757B2 (en) 2015-07-07
HK1214965A1 (zh) 2016-08-12
DK2034985T3 (en) 2015-08-03
FR2903312A1 (fr) 2008-01-11
US20150105352A1 (en) 2015-04-16
ES2543719T3 (es) 2015-08-21
US8518914B2 (en) 2013-08-27
JP5363979B2 (ja) 2013-12-11
DK2921172T3 (en) 2018-10-22
EP2921172B1 (fr) 2018-09-12
FR2903312B1 (fr) 2008-09-26
US20100120720A1 (en) 2010-05-13
PL2034985T3 (pl) 2015-10-30
JP2013166776A (ja) 2013-08-29
ES2702062T3 (es) 2019-02-27
WO2008003864A1 (fr) 2008-01-10
PT2034985E (pt) 2015-09-23

Similar Documents

Publication Publication Date Title
HK1214965A1 (zh) 還原酶抑制劑和法尼基焦磷酸酶合成酶抑制劑的組合用於治療與異戊二烯基化的蛋白的持續存在和/或積累相關的疾病
IL191997A0 (en) Inhibitors of iap
IL232786A0 (en) Inhibitors of e1 enzyme activators
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
IL178104A0 (en) Inhibitors of iap
IL179854A0 (en) Inhibitors of iap
GB0903608D0 (en) Systems and methods for calibration of heart sounds
EP2180891A4 (en) COMBINATION PREPARATION WITH HMG COA REDUCTASE INHIBITORS AND ASPIRIN AND METHOD FOR THE PRODUCTION THEREOF
EP2007383A4 (en) INHIBITORS OF PROTEIN PRENYLTRANSFERASES
SI1833995T1 (sl) Identifikacija tarč RNA z uporabo helikaz
IL193335A0 (en) Method for geolocalization of one or more targets
GB2443533B (en) Determination of sensor distance
ZA200806937B (en) Combination of triazine derivatives and HMG-CoA reductase inhibitors for the treatment of diabetes
IL187730A0 (en) Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
IL187728A0 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
IL187729A0 (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
SI1937696T1 (sl) Postopek za pripravo zaviralcev HMG-CoA reduktaz
EP2212874A4 (en) DEVICE FOR MONITORING AND LOCATING SEMI-TRAILERS
EP2049102A4 (en) POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
EP1871396A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR
AU2013248173A1 (en) Inhibitors of IAP
ZA201006157B (en) Modified release formulations of hmg coa reductase inhibitors
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases